BTAI — BioXcel Therapeutics Balance Sheet
0.000.00%
- $9.73m
- $82.39m
- $2.27m
Annual balance sheet for BioXcel Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 213 | 233 | 194 | 65.2 | 29.9 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | 0.248 | 0.071 | 0.131 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 217 | 237 | 203 | 72.1 | 37.4 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.78 | 2.54 | 2.06 | 1.47 | 0.857 |
Other Long Term Assets | |||||
Total Assets | 220 | 239 | 206 | 73.7 | 38.3 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11.8 | 16.7 | 32.9 | 27.3 | 22.2 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 13.2 | 17.8 | 129 | 130 | 131 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 207 | 222 | 76.8 | -56.5 | -93.1 |
Total Liabilities & Shareholders' Equity | 220 | 239 | 206 | 73.7 | 38.3 |
Total Common Shares Outstanding |